Current evidence supports the use of reactive therapeutic drug monitoring (TDM) to guide treatment changes in inflammatory bowel disease (IBD) patients treated with anti-TNF agents. However, there is less data available on the utility of drug monitoring with vedolizumab (VDZ).

Source link